Fenretinide has potential for GA

Article

Oral drug fenretinide has potential for the treatment of geographic atrophy (GA), but further studies are required.

Oral drug fenretinide has potential for the treatment of geographic atrophy (GA), but further studies are required, according to a paper featured in the journal Retina.

Dr Nathan Mata et al., Retina Associates of Cleveland Inc., Cleveland, Ohio, USA, conducted a two-year, placebo-controlled double-masked trial on 246 patients at 30 clinical sites in the US. Each patient received either 100 mg or 300 mg of oral fenretinide daily to slow lesion growth in GA.

The drug produced dose-dependent reversible reductions in serum RBP-retinol that were linked to trends in reduced lesion growth rates in GA. Patients who received 300 mg of fenretinide demonstrated a mean reduction 0.33 mm2 in the yearly lesion growth rate compared with subjects in the placebo group.

The therapeutic effect reduced the occurrence of choroidal neovascularization. It was not dose-dependent and was consistent with anti-angiogenic properties of fenretinide. These results, in addition to the known safety profile of the drug, warrant further study of fenretinide for GA treatment.

Please visit the journal here to read the abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.